Compositions and methods for treating RAS-mutant cancers
AssigneesMemorial Sloan Kettering Cancer Center, Algen Biotechnologies, Inc.
InventorsChun-Hao Huang, Spencer Charles Knight, Scott Lowe
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to compositions and methods for the treatment of a RAS-mutant cancer. In particular, the present technology relates to administering a therapeutically effective amount of one or more TXNRD1 inhibitors to a subject diagnosed with, or at risk for a RAS-mutant cancer (e.g., RAS-mutant pancreatic cancer).
Claims9
A method for treating a RAS-mutant cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a thioredoxin reductase 1 (TXNRD1) inhibitor selected from the group consisting of auranofin, Piperlongumine, (Diphenyl-2-thienylphosphine-κP) [2-(4-methoxyphenyl) ethynyl]gold (D9), 2-((4-Chlorophenyl) sulfonyl)-6-methoxy-3-nitropyridine (TRi-1), Myricetin, 4-(benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dienone (PMX464), 1-methylpropyl 2-imidazolyl disulfide (PX12), brevetoxin-2, manumycin A, ethaselen, aurothioglucose, protoporphyrin IX, an anti-TXNRD1 antibody, and
- and an additional therapeutic agent, wherein the additional therapeutic agent is gemcitabine or a KRASG12C inhibitor, wherein the KRASG12C inhibitor is sotorasib (AMG 510).
Dependencies are inferred from the claim text.